Follicular thyroid cancer

Follicular thyroid cancer
Other namesFollicular thyroid carcinoma
Micrograph of follicular thyroid carcinoma showing a location where the cancer grows through the fibrous capsule. H&E stain.
SpecialtyENT surgery, oncology

Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50 years of age. Thyroglobulin (Tg) can be used as a tumor marker for well-differentiated follicular thyroid cancer. Thyroid follicular cells are the thyroid cells responsible for the production and secretion of thyroid hormones.

Cause

Associated mutations

Approximately one-half of follicular thyroid carcinomas have mutations in the Ras subfamily of oncogenes, most notably HRAS, NRAS, and KRAS.[1] Mutations in MINPP1 have likewise been observed, as well as germline PTEN gene mutations responsible for Cowden syndrome of which follicular thyroid cancer is a feature. Also, a chromosomal translocation specific for follicular thyroid carcinomas is one between paired box gene 8 (PAX-8), a gene important in thyroid development, and the gene encoding peroxisome proliferator-activated receptor γ 1 (PPARγ1), a nuclear hormone receptor contributing to terminal differentiation of cells. The PAX8-PPARγ1 fusion is present in approximately one-third of follicular thyroid carcinomas, specifically those cancers with a t(2;3)(q13;p25) translocation, permitting juxtaposition of portions of both genes.[1] Tumors tend carry either a RAS mutation or a PAX8-PPARγ1 fusion, and only rarely are both genetic abnormalities present in the same case.[1] Thus, follicular thyroid carcinomas seem to arise by two distinct and virtually nonoverlapping molecular pathways.[1]

Hurthle cell variant

Micrograph of a Hurthle cell neoplasm.

Hurthle cell thyroid cancer is often considered a variant of follicular cell carcinoma.[2][3] Hurthle cell forms are more likely than follicular carcinomas to be bilateral and multifocal and to metastasize to lymph nodes. Like follicular carcinoma, unilateral hemithyroidectomy is performed for non-invasive disease, and total thyroidectomy for invasive disease.

Diagnosis

It is difficult to correctly diagnose follicular neoplasms (FNs) on fine-needle aspiration cytology (FNAC) because it shares many cytological features with other mimicking lesions.[4]

Classification

It is impossible to distinguish between follicular adenoma and carcinoma on cytological grounds. If fine needle aspiration cytology (FNAC) suggests follicular neoplasm, thyroid lobectomy should be performed to establish the histopathological diagnosis. Features sine qua non for the diagnosis of follicular carcinoma are capsular invasion and vascular invasion by tumor cells. Still, focuses of the capsular invasion should be carefully evaluated and discriminated from the capsular rupture due to FNA penetration resulting in WHAFFT (worrisome histologic alterations following FNA of thyroid).

HMGA2 has been proposed as a marker to identify malignant tumors.[5]

Treatment

Treatment is usually surgical, followed by radioiodine.

Initial treatment

  • If follicular cells are found on cytological testing, it is common to carry out hemithyroidectomy to distinguish between follicular adenoma and follicular carcinoma on histopathological examination, proceeding to completion thyroidectomy and postoperative radioiodine ablation where carcinoma is confirmed. This way total thyroidectomy is not carried out unnecessarily.
  • Thyroidectomy is invariably followed by radioiodine treatment at levels from 50 to 200 millicuries following two weeks of a low iodine diet (LID). Occasionally treatment must be repeated if annual scans indicate remaining cancerous tissue. Some physicians favor administering the maximum safe dose (calculated based on a number of factors), while others favor administering smaller doses, which may still be effective in ablating all thyroid tissue. I-131 is used for ablation of the thyroid tissue.

Finding disease recurrence

Some studies have shown that thyroglobulin (Tg) testing combined with neck ultrasound is more productive in finding disease recurrence than full- or whole-body scans (WBS) using radioactive iodine. However, current protocol (in the USA) suggests a small number of clean annual WBS are required before relying on Tg testing plus neck ultrasound. When needed, whole body scans consist of withdrawal from thyroxine medication and/or injection of recombinant human Thyroid stimulating hormone (TSH). In both cases, a low iodine diet regimen must also be followed to optimize the takeup of the radioactive iodine dose. Low dose radioiodine of a few millicuries is administered. Full body nuclear medicine scan follows using a gamma camera. Scan doses of radioactive iodine may be I131 or I123.

Recombinant human TSH, commercial name Thyrogen, is produced in cell culture from genetically engineered hamster cells.

Prognosis

The overall 5-year survival rate for follicular thyroid cancer is 91%, and the 10-year survival rate is 85%.[7]

By overall cancer staging into stages I to IV, follicular thyroid cancer has a 5-year survival rate of 100% for stages I and II, 71% for stage III, and 50% for stage IV.[8]

Compared to other variants of Follicular cell derived thyroid cancer, bone metastases are commonly associated with follicular carcinoma. In the present study a high rate of bone metastases of 34% was observed.[9]

References

  1. 1 2 3 4 Chapter 20 in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). Robbins Basic Pathology. Philadelphia: Saunders. ISBN 978-1-4160-2973-1. 8th edition.
  2. ↑ Kushchayeva Y, Duh QY, Kebebew E, D'Avanzo A, Clark OH (2007). "Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer". Am J Surg. 195 (4): 457–62. doi:10.1016/j.amjsurg.2007.06.001. PMID 18070728.
  3. ↑ Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont JP. "Thyroid and Parathyroid Cancers" Archived 2010-02-28 at the Wayback Machine in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach Archived 2013-10-04 at the Wayback Machine. 11 ed. 2008.
  4. ↑ Han, Kanghee; Ha, Hwa-Jeong; Kong, Joon Seog; Kim, Jung-Soon; Myung, Jae Kyung; Koh, Jae Soo; Park, Sunhoo; Shin, Myung-Soon; Song, Woo-Tack; Seol, Hye Sil; Lee, Seung-Sook (March 2018). "Cytological Features That Differentiate Follicular Neoplasm from Mimicking Lesions". Journal of Pathology and Translational Medicine. 52 (2): 110–120. doi:10.4132/jptm.2018.01.17. ISSN 2383-7837. PMC 5859246. PMID 29374960.
  5. ↑ Belge G, Meyer A, Klemke M, et al. (2008). "Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias". Genes Chromosomes Cancer. 47 (1): 56–63. doi:10.1002/gcc.20505. PMID 17943974.
  6. ↑ Hegazy MA, Khater AA, Setit AE, et al. (2007). "Minimally invasive video-assisted thyroidectomy for small follicular thyroid nodules". World J Surg. 31 (9): 1743–50. doi:10.1007/s00268-007-9147-7. PMID 17653588. S2CID 19818345.
  7. ↑ Numbers from National Cancer Database in the US, from Page 10 in: F. Grünwald; Biersack, H. J.; Grںunwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN 978-3-540-22309-2. (Note:Book also states that the 14% 10-year survival for anaplastic thyroid cancer was overestimated
  8. ↑ cancer.org > Thyroid Cancer By the American Cancer Society. In turn citing: AJCC Cancer Staging Manual (7th ed).
  9. ↑ Pal, Pooja; Singh, Bikramjit; Kane, Shubhada; Chaturvedi, Pankaj (March 2018). "Bone Metastases in Follicular Carcinoma of Thyroid". Indian Journal of Otolaryngology and Head & Neck Surgery. 70 (1): 10–14. doi:10.1007/s12070-017-1170-x. ISSN 2231-3796. PMC 5807283. PMID 29456936.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.